Intuitive Surgical, Inc. (ISRG)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 2.31% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Intuitive Surgical (ISRG) and JNJ Give Jim Cramer More Than Valuation to Consider
- Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, AppFolio, Delek US Holdings, Flutter Entertainment, Honeywell Aerospace, Intuitive Surgical, Marvell, NetApp, and More
- What Could Lift ISRG Stock?
- Intuitive Surgical (ISRG): Is Its Robotic-Surgery Moat Still Untouchable?
- Can ISRG Offset China Weakness With Expansion in India and Japan?
- Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
- Is Wall Street Dead Wrong About Intuitive Surgical? Here's My Honest Answer.
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Intuitive Surgical, Inc..
Full ISRG Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.